Figure 2.

Plasma and brain ISF distribution of systemically administered 4G8 and its effect on ¹²⁵I-Aβ40 clearance from brain ISF. A, Plasma 4G8 levels determined with ELISA within 120 h in mice that received 4G8 (200μg) intraperitoneally at 0 and 48 h. B, Brain ISF 4G8 levels in mice in A at 1 and 120 h of 4G8 treatment. C, D, Clearance of ¹²⁵I-Aβ40 (40 nm) via BBB transport and ISF bulk flow within 30 min of ¹²⁵I-Aβ40/¹⁴C-inulin microinjections into brain ISF in mice at 1 h (C) and 120 h (D) of 4G8 treatment as in A. E, Formation of ¹²⁵I-Aβ40–4G8 complexes in mouse brain ISF determined by Tris-tricine native PAGE of the aqueous brain extracts 30 min after ¹²⁵I-Aβ40 (120 nm) microinfusion into brain ISF and after either 1 h (left) or 120 h (right) of 4G8 treatment as in A. Mean ± SEM; n = 3–5. *p < 0.001 and **p < 0.05.